Myeloma Clinical Trials

There are hundreds of clinical trials for patients with Multiple Myeloma, Smoldering Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS) around the US. Below is a featured listing of clinical trials to help you get started. Please use the options on the side bar to find trials based on your diagnosis.


Create Your Account

Create your account today and get matched to eligible myeloma clinical trials.

  • Find clinical trials in your home town or around the country.
  • Find a myeloma specialist.
  • Receive alerts when new trials become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment.

Learn more about this trial


Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life.

No travel is required to participate in this observational trial.

Learn more about this trial


Selinexor Treatment of Refractory Myeloma

This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd), both dosed twice weekly in each four-week cycle, in patients with MM previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and daratumumab.

Learn more about this trial


PRospective Multiple Myeloma Impact Study (PROMMIS)

We are doing this study to learn if the MMprofiler genomic test can help your doctor in making decisions about your treatment.

Learn more about this trial


Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

This study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with relapsed or refractory multiple myeloma.

Learn more about this trial


Recently Updated

A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

The purpose of this trial is to evaluate the safety and tolerability of KITE-585, an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA.

Learn more about this trial


Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome (PCROWD)

The PCROWD is part of the Center for Prevention of Progression of Blood Cancers (CPOP), a research initiative at Dana-Farber Cancer Institute focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease.

No travel is required to participate in this observational trial.

Learn more about this trial


Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

The purpose of this study is to test whether RO6870810 is safe at different dose levels, to find out what effects, good or bad, RO6870810 has on you and your disease as monotherapy or in combination with daratumumab in participants with relapsed/refractory multiple myeloma.

Learn more about this trial


Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of subjects achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.

Learn more about this trial